TEIJIN LTD/ JP3544000007 /
16/07/2024 09:30:23 | Chg. -0.10 | Volume | Bid11:57:34 | Ask11:57:34 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
7.75EUR | -1.27% | 1 Turnover: 7.75 |
7.75Bid Size: 646 | 7.90Ask Size: 632 | 1.51 bill.EUR | - | - |
GlobeNewswire
13/05
Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparath...
GlobeNewswire
09/05
Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with...
GlobeNewswire
31/01
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for ...
GlobeNewswire
29/11/2023
Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan
Newsfile Corp
21/11/2022
The "Electrification" of the World: Battery Safety and Efficiency Demands Grow Amidst Lofty Global E...
GlobeNewswire
09/09/2020
Radius Health Announces Scientific Presentations on abaloparatide at ASBMR 2020 Annual Meeting